Topic

Blue Cross Blue Shield (BCBS Association)

A collection of 103 issues

How to Get Gattex (teduglutide) Covered by Blue Cross Blue Shield of Illinois: Prior Authorization, Appeals, and State Protections

Answer Box: Getting Gattex Approved in Illinois To get Gattex (teduglutide) covered by Blue Cross Blue Shield of Illinois, you need prior authorization showing short bowel syndrome with parenteral nutrition dependence. Submit clinical documentation including PN logs, specialist attestation, and failed alternative therapies. If denied, you have 60 days to
6 min read

How to Get Xenpozyme (olipudase alfa-rpcp) Covered by Blue Cross Blue Shield in Virginia: Complete Timeline & Appeal Guide

Quick Answer: Getting Xenpozyme Covered by Blue Cross Blue Shield in Virginia Xenpozyme (olipudase alfa-rpcp) requires prior authorization from Blue Cross Blue Shield Virginia, typically decided within 72 hours for standard requests. To get approved: (1) Ensure you have documented ASMD diagnosis with genetic/enzyme confirmation, (2) Submit complete prior
6 min read

How to Get Juxtapid (Lomitapide) Covered by Florida Blue Cross Blue Shield: PA Forms, Appeals & Success Tips

Answer Box: Getting Juxtapid Covered by Florida Blue Juxtapid (lomitapide) requires prior authorization from Florida Blue and is typically placed on Tier 6 (Non-Preferred Specialty). To get approval: 1) Your doctor must submit genetic testing confirming homozygous familial hypercholesterolemia (HoFH) with bi-allelic pathogenic variants, 2) Document failed trials of PCSK9
7 min read

How to Get Natpara Covered by Blue Cross Blue Shield in North Carolina: Complete Appeals Guide with Forms and Deadlines

Answer Box: Getting Natpara Covered by Blue Cross Blue Shield in North Carolina Important Update: Natpara manufacturing ended December 2024, with the Special Use Program ceasing December 31, 2025. New patient requests are typically denied due to discontinued availability. For existing patients transitioning off Natpara, focus on documenting medical necessity
6 min read